Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242097 | 1.00 | HSD11B1 (0.43) | HSD11B1LMNAMAPTEPHX2SRD5A2 | |
| SCHEMBL240795 | 1.00 | HSD11B1 (0.43) | HSD11B1LMNAMAPTEPHX2SRD5A2 | |
| SCHEMBL240876 | 1.00 | HSD11B1 (0.43) | HSD11B1LMNAMAPTEPHX2SRD5A2 | |
| SCHEMBL2757124 | 1.00 | HSD11B1 (0.43) | HSD11B1LMNAMAPTEPHX2SRD5A2 | |
| SCHEMBL240767 | 0.89 | HSD11B1 (0.41) | HSD11B1LMNAMAPTEPHX2SRD5A2 | |
| SCHEMBL14402787 | 0.86 | LMNA (0.39) | HSD11B1LMNAMAPTEPHX2SRD5A2 | |
| SCHEMBL14402775 | 0.86 | LMNA (0.39) | HSD11B1LMNAMAPTEPHX2SRD5A2 | |
| SCHEMBL242092 | 0.85 | EPHX2 (0.46) | HSD11B1LMNAMAPTEPHX2 | |
| SCHEMBL240428 | 0.78 | HSD11B1 (0.42) | HSD11B1LMNAMAPTEPHX2MEN1 | |
| SCHEMBL1168346 | 0.76 | POLB (0.42) | HSD11B1MAPTEPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885LMNA 2424/4885MAPT 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.